Mr. Chris Seto reports

SPECTRAL MEDICAL INC. ANNOUNCES RESULTS OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

Spectral Medical Inc. has released the results of its annual and special meeting of shareholders held on June 7, 2023. The company confirms that all resolutions put forward in the management information circular dated May 5, 2023, to its shareholders were approved, other than the proposed share consolidation.

Results of the matters voted on at the meeting are set out herein.

Election of directors

Spectral's seven director nominees were elected.

                 VOTING RESULTS FOR ELECTION OF DIRECTORS

Nominee                 Votes for (per cent)      Votes withheld (per cent)

Anthony Bihl III                      56.14%                         43.86%
Jan D'Alvise                          65.61%                         34.39%
Jun Hayakawa                          70.22%                         29.78%
John Nosenzo                          56.51%                         43.49%
Chris Seto                            56.40%                         43.60%
William Stevens                       64.55%                         35.45%
Paul Walker                           86.29%                         13.71%

Appointment of auditor

PricewaterhouseCoopers LLP, chartered accountants, was reappointed as auditor of Spectral.

Votes for:  93.77 per cent

Votes withheld:  6.23 per cent

Adoption of omnibus long-term incentive plan

A resolution approving the readoption of the corporation's omnibus long-term incentive plan, as more particularly described in the circular, was passed.

Votes for:  55.48 per cent

Votes against:  44.52 per cent

Approval of consolidation

A special resolution authorizing the future amendment of the articles of the company to consolidate all of the company's issued and outstanding common shares, as more particularly described in the circular, was not approved.

Votes for:  60.05 per cent

Votes against:  39.95 per cent

About Spectral Medical Inc.

Spectral is a phase 3 company seeking U.S. Food and Drug Administration approval for its unique product for the treatment of patients with septic shock, Toraymyxin (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream, and is guided by the company's endotoxin activity assay (EAA), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 340,000 patients to date. In March, 2009, Spectral obtained the exclusive development and commercial rights in the United States for PMX, and in November, 2010, signed an exclusive distribution agreement for this product in Canada. In July, 2022, the U.S. FDA granted breakthrough device designation for PMX for the treatment of endotoxemic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year.

Spectral is listed on the Toronto Stock Exchange under the symbol EDT.

We seek Safe Harbor.